Skip to main content
 

AHA and BMS/Pfizer: Identifying undiagnosed, asymptomatic AFib

AHA and BMS/Pfizer: Identifying undiagnosed, asymptomatic AFib

It is estimated that more than 5 million people in the United State are diagnosed with NVAF and an additional 3 million have AFib and don’t know it (Colilla S et al. Am J Cardiol.2014;pii: S0002-9149(13)-1288). The BMS/Pfizer Alliance and AHA are working together to identify undiagnosed patients and provide digital tools to manage the condition. The first phase of this study involves the development of a screening tool using a combination of pharmacy, hospital, claims and EHR data in order to identify patients at high risk for having or developing AFib. AHA and its team of expert advisors are designing the tool with the intent of practical clinical implementation and scalability. Success of this tool has the potential to save millions of lives by reducing the risk of stroke in AFib patients who don’t even know they have AFib.

More News

  • Highlights from the Health Innovation Pavilion at AHA22

    The Health Innovation Pavilion at the AHA Scientific Sessions 22 included a…

  • Health Tech + Health Equity: tackling complex health disparities with scalable solutions, ensuring equitable health for all.

    Individuals of minority cultural and socio-economic groups in the U.S. are traditionally…

  • AHA and BMS/Pfizer: Identifying undiagnosed, asymptomatic AFib

    It is estimated that more than 5 million people in the United…

  • Google and AHA Collaborate on Augmented Reality Hands-Only CPR Trainer

    The American Heart Association has collaborated with Google to develop an augmented…

Sign up for our mailing list